SQLite Web: event_store.db

Update row sig_90f16e5f9f56 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160364.txt","as_of":"2026-04-18T03:05:05.644967+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160364.txt","company":"Tyra Biosciences, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160364.txt","article_chars":3713,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_6bdfe54f0205036f","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160364.txt","content_type":"text/plain","enriched_at":"2026-04-18T03:25:55.906651+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"DEFA14A","final_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160364.txt","html_truncated":true,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160364.txt","source_event_id":"evt_aa6a9083d8e4","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"DEFA14A","fp":"f9f453f5c0124f8c","kind":"sec_filing","published_at":"20260417","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-02","2026-05-18","2026-05-28","2026-12-31"],"entities":[{"asset_class":"equity","name":"Tyra Biosciences, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"other","name":"Ernst & Young LLP","relevance":"medium","symbol":"","type":"auditor"},{"asset_class":"other","name":"Habib J. Dable","relevance":"medium","symbol":"","type":"director_nominee"},{"asset_class":"other","name":"Susan Moran, M.D., M.S.C.E.","relevance":"medium","symbol":"","type":"director_nominee"},{"asset_class":"other","name":"Robert More","relevance":"medium","symbol":"","type":"director_nominee"},{"asset_class":"other","name":"SEC (U.S. Securities and Exchange Commission)","relevance":"medium","symbol":"","type":"regulator"}],"event_type":"listing","information_gaps":["What specifically changed versus the prior known state is not provided in the signal text (no prior filing comparison content included).","The filing\u2019s amendment number is shown as blank: \u201c(Amendment No. )\u201d.","The filing\u2019s \u201cFiled by the Registrant\u201d vs \u201cFiled by a Party other than the Registrant\u201d checkbox state is not explicitly confirmed in the provided text.","No financial guidance or financial implications are disclosed in the provided excerpt beyond auditor ratification and governance proposals."],"key_facts":["Form type: DEFA14A (Schedule 14A proxy statement).","Issuer: Tyra Biosciences, Inc.","Annual Meeting date/time: Thursday, May 28, 2026 at 10:00 AM Pacific Time.","Stockholders of record date: April 2, 2026.","Board recommends a vote FOR proposals 1 and 2.","Proposal 1: elect three directors as Class II directors for three-year terms expiring at the 2029 Annual Meeting (named nominees: Habib J. Dable; Susan Moran, M.D., M.S.C.E.; Robert More).","Proposal 2: ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.","Proposal 3: transact such other business as may properly come before the Annual Meeting."],"numeric_claims":[{"label":"Annual meeting date","value":"2026-05-28"},{"label":"Annual meeting time (PT)","value":"10:00 AM Pacific Time"},{"label":"Record date","value":"2026-04-02"},{"label":"Fiscal year end for auditor ratification","value":"2026-12-31"},{"label":"Control number request deadline for paper materials","value":"2026-05-18"}],"primary_claim":"Tyra Biosciences, Inc. filed Form DEFA14A (Schedule 14A proxy statement) for its annual meeting on May 28, 2026, with proposals to elect three directors and ratify Ernst & Young LLP.","relevance_score":0.62,"sentiment":"neutral","source_quality":"high","summary":"Tyra Biosciences, Inc. filed a Schedule 14A proxy statement (DEFA14A) with the SEC for its annual meeting of stockholders. The filing includes proposals to elect three Class II directors and to ratify Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.","topics":["SEC filing","proxy statement","annual meeting of stockholders","director election","independent auditor ratification","corporate governance"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form DEFA14A \u00b7 Tyra Biosciences, Inc. \u00b7 Filed 20260417","ticker":"TYRA","tickers":["TYRA"],"title":"TYRA filed DEFA14A","url":"https://www.sec.gov/Archives/edgar/data/1863127/0001193125-26-160364.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel